Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
A phase 1/2 trial of Elironrasib, Daraxonrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Overview
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC is a phase 1/2 interventional study registered as NCT06162221 by Revolution Medicines, Inc., with 616 participants planned, started 2024-01-18 and due to reach its primary completion in 2027-06. Interventions recorded: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Cisplatin.
- TrialStudy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu
Shares Revolution Medicines, Pemetrexed, Cisplatin, Carboplatin.
- TrialStudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.